Skip to main content
Equibles
MDGL logo

MDGL · Madrigal Pharmaceuticals, Inc. · Documents

Track MDGL — free

Use MDGL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MDGL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$427.39 +2.18 (+0.51%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Russell 1000 member Rebalance outlook locked
Market Cap
$9.93B
Shares
23.23M
Volume · Nov 13 441.32K Avg daily vol (3M) 354.09K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $958.4M up 432.1% 10-K filed Feb 19, 2026 Quarterly report FY2026 Q3 Revenue $431.27M up 50.1% 10-Q filed Nov 3, 2026 Latest results Financial results 8-K filed Nov 3, 2026 Earnings call Q3 2026 earnings call Held Nov 3, 2026
2026
Nov 3
Earnings call
Sales reach $431.3 million as company posts first profitable quarter

Madrigal Pharmaceuticals, Inc. reported third-quarter 2026 net sales of $431.3 million, up 50% year-over-year, and its first profitable quarter, with net income of $55.4 million.

3 source passages
Third quarter of 2026, net sales were $431.3 million, up 50% year-over-year, with year-to-date net sales of $1.1 billion. The third quarter marked another important milestone for Madrigal, our first quarter profitability. We reported net income of $55.4 million compared to a net loss of $114.2 million. Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Rezdiffra revenue rises as quarterly net income turns positive

Madrigal Pharmaceuticals recorded $431.3 million in net product revenue for the three months ended September 30, 2026, versus $287.3 million in the corresponding period in 2025, and reported $55.4 million in net income.

Revenue $431.27M ▲ 50.1% Net income $55.44M Diluted EPS $1.83
Read from the MD&A section
3 source passages
About Madrigal Pharmaceuticals, Inc. We recorded $431.3 million of product revenue, net for the three months ended September 30, 2026, compared to $287.3 million in the corresponding period in 2025. The increase was driven by increased demand for Rezdiffra in the United States in 2026. Although we generated net income of $55.4 million for the three months ended September 30, 2026, we have incurred losses since inception Open the document at this passage
Nov 3
Current report 8-K
Financial results

Madrigal Pharmaceuticals, Inc. reported third-quarter 2026 Rezdiffra net sales of $431.3 million, up 50%, and achieved its first profitable quarter; cash, cash equivalents, restricted cash and marketable securities were $961.8 million as of Sept. 30, 2026.

Jul 30
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $364.25M ▲ 71.2% Net loss $57.94M Diluted EPS -$1.99
May 6
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $311.34M ▲ 126.8% Net loss $94.39M Diluted EPS -$3.25
Apr 28
Proxy statement DEF 14A Meeting Jun 17, 2026
Proxy statement AI summary on its way
Feb 19
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $958.4M ▲ 432.1% Net loss $288.28M Diluted EPS -$12.85
2025
Feb 26
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $180.13M Net loss $465.89M Diluted EPS -$21.90
2024
Showing 1–50 of 130 documents
Key facts CIK 1157601 CUSIP 558868105 13F (30d) 343 filings 308 filers Visit website Investor relations